Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of cryptotanshinone in preparing medicine for preventing and treating cachexia skeletal muscle atrophy

A technology for cryptotanshinone and cachexia, which is applied in the application field of cryptotanshinone in the preparation of drugs for preventing and treating cachexia skeletal muscle atrophy, can solve the problems such as no relevant reports, and achieve the effects of improving myotube atrophy and inhibiting expression.

Inactive Publication Date: 2020-05-19
SHANGHAI SIXTH PEOPLES HOSPITAL
View PDF5 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Cryptotanshinone (Cryptotanshinone) is a monomer isolated from tanshinone with antibacterial, anti-inflammatory, and cooling effects. It is mostly used clinically for the treatment of coronary heart disease, anti-infection, hepatitis, leprosy or diabetes, etc. It is currently used in the treatment of cachexia or cachexia skeletal muscle atrophy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of cryptotanshinone in preparing medicine for preventing and treating cachexia skeletal muscle atrophy
  • Application of cryptotanshinone in preparing medicine for preventing and treating cachexia skeletal muscle atrophy
  • Application of cryptotanshinone in preparing medicine for preventing and treating cachexia skeletal muscle atrophy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] This embodiment detects the influence of cryptotanshinone on the activity of C2C12 myotubes, and the specific experimental contents and results are as follows:

[0030] Mouse-derived C2C12 myoblasts were mixed with 1×10 4 Cells were seeded in a 96-well plate at a density of 100 μl DMEM complete medium containing 10% FBS, and when the cells reached 90% confluence, the medium was replaced with DMEM differentiation medium containing 2% horse serum, and cultured 3d to form myotubes. Three replicate wells were prepared for each concentration of cryptotanshinone (1, 3, 10, 30, 100 μM), and a blank control group containing the same amount of DMSO was set at the same time. After incubation for 48 hours, the original medium was discarded, and 100 μl of CCK-8 DMEM medium containing 10 μg / ml concentration was replaced. After incubation at 37°C for 1 hour, the optical density (OD) was measured at 450 nm to obtain the effect of cryptotanshinone on the activity of C2C12 myotubes. i...

Embodiment 2

[0033] This example uses morphology to study the protective effect of cryptotanshinone on CT26 cell supernatant-induced C2C12 myotube atrophy. The specific experimental content and results are as follows:

[0034] 1. Obtaining inducers: CT26 cell supernatants were used as inducers for the in vitro model of skeletal muscle atrophy. Mouse-derived colon adenocarcinoma CT26 cells were mixed with 1×10 6 The density of cells was inoculated in a petri dish with a diameter of 10 cm, and cultured in DMEM complete medium containing 10% FBS. When the cell confluence reached about 90%, the complete medium was discarded, washed twice with PBS, and cultured The base was replaced with DMEM differentiation medium containing 2% horse serum, and the culture was continued for 36 h. The supernatant of the cultured CT26 cells was collected and centrifuged at 4500 rpm for 5 min at 4°C. The obtained CT26 cell supernatant was diluted 1:4 in In the differentiation medium, it is used as the myotube at...

Embodiment 3

[0046] In this example, Western blot was used to detect the influence of cryptotanshinone on STAT3 protein phosphorylation and E3 ubiquitin ligase. The specific experimental content and results are as follows:

[0047] (1) Mouse myoblast C2C12 was treated with 2×10 5 The density of cells was seeded in 6-well plates, and 2% horse serum induced C2C12 myoblasts to differentiate into multinucleated myotubes.

[0048] (2) After pretreatment with different concentrations of cryptotanshinone (2.5, 5, 10 μM) for 2 hours, add 1 / 5 of the supernatant of CT26 cells to induce myotubes for 48 hours (the TCM-induced muscle atrophy time was explored through preliminary experiments, such as image 3 A, it was verified that the effect of myotube cells was obvious after induction for 48 hours).

[0049] (3) Cells were collected, lysed on ice with Western and IP lysates for 30 min, and centrifuged at 12000 rpm for 10 min at 4°C.

[0050] (4) BCA method was used for protein quantification, and t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides application of cryptotanshinone in preparing a medicine for preventing and treating cachexia skeletal muscle atrophy. The medicine comprises an active component of cryptotanshinone and further comprises pharmaceutically acceptable auxiliary materials. Cryptotanshinone is capable of alleviating C2C12 myotube atrophy, and in addition, remarkably reducing expression of proteinsp-STAT3, MuRF1 and Atrogin-1 in muscles to inhibit degradation of skeletal muscle proteins, and novel ideas are provided for preparing medicines for treating and preventing cachexia skeletal muscle atrophy.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to the application of cryptotanshinone in the preparation of drugs for preventing and treating cachexia skeletal muscle atrophy. Background technique [0002] Cachexia is a wasting syndrome caused by multiple factors such as tumor or other chronic diseases including injury, organ failure, sepsis, rheumatoid arthritis and HIV / AIDS, accompanied by weight loss and energy and protein metabolism imbalance . The most obvious manifestation of cachexia is loss of muscle and fat mass. This persistent muscle wasting impairs daily life function and activities, increases the toxicity and complications of anticancer therapy, and can lead to decreased activity, impaired breathing, and ultimately death. To date, there are no effective medical interventions to completely reverse cachexia, nor are there approved drug therapies. Although the only definitive cure for cachexia is to cure the primary disea...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/58A61P21/00A61P19/08
CPCA61K31/58A61P19/08A61P21/00
Inventor 郭澄杨全军张洪
Owner SHANGHAI SIXTH PEOPLES HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com